Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 10,857 matching trials from the live ClinicalTrials.gov search.
Filters: Nashville, Tennessee Clear all
Completed Not applicable Interventional Results available

Personalized Assessment of Client Experiences

NCT04369924
View directory record Official record
Conditions
Mental Disorder in Adolescence
Interventions
Unidimensional Measurement-Based Care, Multidimensional Measurement-Based Care
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
11 Years to 17 Years
Enrollment
1,261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn

NCT01720524
View directory record Official record
Conditions
Pulmonary Hypertension, Familial Persistent, of the Newborn
Interventions
placebo, iv sildenafil
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Days to 4 Days
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
20
States / cities
Little Rock, Arkansas • Sacramento, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Trial of rPA-102 Vaccine in Healthy Adult Volunteers

NCT00100724
View directory record Official record
Conditions
Anthrax
Interventions
rPA102
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years to 55 Years
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
12
States / cities
Torrance, California • Atlanta, Georgia • Lexington, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2006 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis

NCT01620255
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, PF-00547659 SC Injection
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
357 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
99
States / cities
Scottsdale, Arizona • La Jolla, California • Orange, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 31, 2026, 1:34 PM EDT
Recruiting Phase 3 Interventional

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

NCT03959085
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions
Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate
Procedure · Biological · Drug + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 25 Years
Enrollment
5,951 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
203
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Active, not recruiting Phase 3 Interventional

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

NCT03180268
View directory record Official record
Conditions
Grade 2 Meningioma, Intracranial Meningioma
Interventions
Biospecimen Collection, Clinical Observation, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Proton Beam Radiation Therapy, Quality-of-Life Assessment
Procedure · Other · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
198
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 162 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Terminated Phase 2 Interventional Results available

An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

NCT01602120
View directory record Official record
Conditions
Geographic Atrophy
Interventions
Lampalizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
60 Years to 89 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
41
States / cities
Tucson, Arizona • Beverly Hills, California • Campbell, California + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 31, 2026, 1:34 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

NCT06745323
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC)
Interventions
Tarlatamab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
12
States / cities
Los Angeles, California • Plainville, Connecticut • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational

Cytochrome C Oxidase Activity in Newly Diagnosed Glioblastoma Multiforme (GBM)

NCT02997423
View directory record Official record
Conditions
Glioblastoma
Interventions
Not listed
Lead sponsor
University of Iowa
Other
Eligibility
21 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 31, 2026, 1:34 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH

NCT04280523
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
ESR-specific PET scan
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
13 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery

NCT01969058
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Isotretinoin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

NCT01056276
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bendamustine, Bortezomib, Dexamethasone
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
13
States / cities
Thousand Oaks, California • Fort Myers, Florida • Baton Rouge, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

NCT00529568
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
eltrombopag, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)

NCT01709149
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
CK-2017357, Placebo tablets, Riluzole
Drug · Other
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years and older
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
44
States / cities
Phoenix, Arizona • La Jolla, California • Orange, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Registry for Integrative Medicine Interventions Effectiveness

NCT01754038
View directory record Official record
Conditions
All Conditions of Integrative Medicine Clinic Patients
Interventions
Not listed
Lead sponsor
BraveNet
Other
Eligibility
18 Years and older
Enrollment
5,069 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Santa Monica, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 31, 2026, 1:34 PM EDT
Recruiting Not applicable Interventional

Function After Anterior Cervical Discectomy and Fusion Surgery: Timing of Physical Therapy

NCT06202443
View directory record Official record
Conditions
Cervical Spine Degeneration, ACDF Surgery
Interventions
Early PT, Delayed PT
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Honolulu, Hawaii • Nashville, Tennessee • Fort Sam Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Recruiting Phase 1 Interventional

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

NCT06994676
View directory record Official record
Conditions
High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Interventions
CBX-250
Drug
Lead sponsor
Crossbow Therapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
11
States / cities
Duarte, California • Palo Alto, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Web-Enhanced Guideline Implementation for Post MI CBOC Patients

NCT00126750
View directory record Official record
Conditions
Myocardial Infarction, Comorbidity
Interventions
VA MI Plus Interactive
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
847 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 31, 2026, 1:34 PM EDT
Completed Phase 2 Interventional

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

NCT06522997
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
BAY3283142, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
24
States / cities
Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The ADAPT Trial: Adapting Evidence-Based Obesity Interventions in Community Settings

NCT06546696
View directory record Official record
Conditions
Childhood Obesity
Interventions
Competency Based Approaches to Community Health (COACH)
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 12 Years
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 1:34 PM EDT
Terminated Phase 1 Interventional

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

NCT04073615
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Rivoceranib, Trifluridine/Tipiracil
Drug
Lead sponsor
Elevar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
4
States / cities
Sarasota, Florida • Chicago, Illinois • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 2, 2024 · Synced Oct 31, 2026, 1:34 PM EDT
Completed No phase listed Observational

Review of Molecular Profiling-Real Time Polymerase Chain Reaction (Rt-Pcr) in Unknown Primary Cancer

NCT00876408
View directory record Official record
Conditions
Unknown Primary Cancer
Interventions
Not listed
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Oct 31, 2026, 1:34 PM EDT
Recruiting Phase 3 Interventional

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

NCT03678025
View directory record Official record
Conditions
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Abiraterone, Bicalutamide, Degarelix, Docetaxel, Flutamide, Goserelin Acetate, Histrelin Acetate, Leuprolide Acetate, Nilutamide, Orchiectomy, Prednisone, Quality-of-Life Assessment, Radiation Therapy, Radical Prostatectomy, Triptorelin
Drug · Procedure · Other + 1 more
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older · Male only
Enrollment
1,273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2036
U.S. locations
334
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 253 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 31, 2026, 1:34 PM EDT
Terminated No phase listed Observational

This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid Tumors to Determine Suitability for Repertoire Immune Medicines Treatment Protocols.

NCT05061940
View directory record Official record
Conditions
Head and Neck Cancer, Melanoma, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Lung Cancer, Nonsmall Cell, Melanoma (Skin)
Interventions
Tumor Profiling
Diagnostic Test
Lead sponsor
Repertoire Immune Medicines
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 31, 2026, 1:34 PM EDT